Shanghai MicroPort MedBot (Group) Co., Ltd.
上海微创医疗机器人（集团）股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") hereby informs the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment and analysis of the unaudited consolidated management accounts of the Group for the year ended 31 December 2024 (the "**Reporting Period**") and the data currently available to the Board, the Board expects that the revenue of the Company for the Reporting Period will achieve a year-on-year growth of approximately 145% to 155% as compared to the year ended 31 December 2023. This increase is attributable to the strong growth of sales in both domestic and overseas markets.

1. For the domestic market, the Company has made intensive efforts to maintain the Toumai Laparoscopic Surgical Robot as the first in terms of the market share of similar products, while the R-ONE Vascular Interventional Surgical Robot has also gained recognition in the market and achieved a breakthrough in commercialisation after approval for launch; and

2. For overseas markets, in the first year of Toumai's overseas market exploration, it not only expanded the emerging markets such as Asia, Africa and Latin America, but also achieved sales breakthroughs in high-end markets in Europe, with overseas commercialisation orders exceeding 20 units and more than 10 commercially installed units; the overseas sales of SkyWalker Orthopedic Surgical Robot continued to maintain rapid growth, with global orders exceeding 20 units and installation volume doubling year-on-year.

The Board expects that the Group will record an adjusted net loss[1] ranging from RMB435 million to RMB521 million for the year ended 31 December 2024 (the year ended 31 December 2023: RMB869 million). Such decrease in loss is mainly attributable to (i) the rapid growth in revenue; and (ii) the significant decrease in operating expenses under various cost reduction and efficiency improvement measures.

The figures contained in this announcement represent only the preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group and the other information currently available to the Board, which have neither been audited or reviewed by the independent auditor of the Company nor confirmed by the audit committee of the Company. As the Company is still in the process of finalising its financial results for the Reporting Period, the final results for the Reporting Period may be subject to changes and may differ from the figures disclosed in this announcement. The final results of the Company for the Reporting Period and other details of the Group's operations are expected to be disclosed in the annual results announcement of the Company for the Reporting Period to be published before the end of March 2025. Shareholders of the Company and potential investors are advised to read the audited annual results announcement carefully after its publication.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 3 March 2025

As at the date of this announcement, the executive Directors are Dr. He Chao and Ms. Fang Cong, the non-executive Directors are Mr. Sun Hongbin, Mr. Chen Xinxing and Mr. Chen Chen, and the independent non-executive Directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Chung Wai Man.

1 The Company uses adjusted net loss as a non-HKFRS measure, which does not take into account the impact on losses attributable to share-based payment expenses, changes in the fair value of financial instruments and impairment losses on equity-accounted investees.